Clinical Trials Logo

Clinical Trial Summary

Across the United States, thousands of children and adolescents suffer from eating disorders. Among young women alone, an estimated 2 to 4 percent are dealing with anorexia nervosa. Anorexia nervosa also has the highest mortality rate of any psychiatric disorder and produces a six-fold increased risk for death. Unfortunately, study shows that current treatments are only successful with 25 percent of patients and no eating disorder prevention program has been found to reduce future onset of anorexia nervosa. The goal of this study is to conduct a highly innovative pilot study that will identify risk factors that predict future onset of anorexia nervosa and investigate how the risk processes for anorexia nervosa are different from the risk processes for bulimia nervosa. The proposed pilot study will: - Compare 30 healthy adolescent girls at high risk for anorexia nervosa to 30 healthy adolescent girls at high risk for bulimia nervosa, and 30 healthy adolescent girls at low risk for eating disorder in an effort to document risk processes that are present in early adolescence before anorexia nervosa typically emerges. - Test whether elevations in the hypothesized risk factors predict future onset of anorexia nervosa over a four-year follow-up.


Clinical Trial Description

Data verification, preliminary analyses, and missing data. Data will be entered twice and discrepancies corrected. Preliminary analyses will examine out-of-range values or unusual distributions. Reaction time data that are +/-2 SD from the mean will be excluded from analyses, following convention. All data will be analyzed regardless of missing follow-up data. Missing data will be addressed using maximum likelihood estimation, multiple imputation, or Type I and random right censoring. Maximum likelihood procedures, as well as multiple imputation, can provide unbiased estimates even in instances of substantial attrition (Shafer & Graham, 2002). Multiple imputation procedures will follow best-practice recommendations (Graham et al., 2007) and missing values will be imputed using the mice package in R (van Buuren & Groothuis-Oudshoorn, 2011). Observed and imputed datasets will be compared to ensure they show similar distributions and will be analyzed separately and results combined to obtain inferential tests based on average parameter estimates and standard errors (Rubin, 2009). Image processing. MR scans will be performed with a 3T GE MR 750 scanner system. Blood oxygen-level dependent, echo-planar images (BOLD-EPI) will be acquired with T2*-weighted multiband (simultaneous multi-slice) acquisition sequence (TR=2000ms, TE=30ms, flip angle=53, multiband factor=4, 2.2mm isotropic voxel size; 64 8x8 axial slices with no gap). Slices will be tilted ~30 degrees relative to the AC-PC line. A rear-projection system will present visual stimuli and a button box will assess behavioral responses. Timing and delivery of the experimental tasks to the stimulus display equipment will be controlled via a MacBook Pro using Psychtoolbox software run on MATLAB. Data analysis will be performed primarily using Statistical Parametric Mapping 12 (SPM12). We will either rescan participants for whom we have poor data or recruit a replacement. Preprocessing will include rigid-body transformation (realignment) and coregistration to the first functional image of each run. Images within each run will be aligned to the first image of that run, and then aligned to the first image from the first run, using a 6-parameter rigid body algorithm in SPM12. The MP-RAGE scan will then be skull-stripped (with FSL's brain extraction tool) and normalized to a high-resolution, T1-weighted template yielding a set of normalization parameters. Parameters will then be applied to all functional and anatomical images, which will then be smoothed with a 6-mm smoothing kernel. We considered using age-specific brain template (Wilke et al., 2003), however, use in analyses with adolescents did not improve data quality. Statistical comparisons will be computed using a general linear model in SPM12 at the subject level, then imported to second level random effects models. A Monte Carlo simulation using true smoothness will be used to compute voxel-wise and cluster-size thresholds for our data that adjust for multiple comparisons to achieve a family-wise Type I error rate of 5%.We will control for hunger and menstrual phase. We will correct fMRI scans for motion, scanner, and cerebrospinal fluid artifacts using independent component analysis (ICA) denoising (Kelly et al., 2010). We will use Artifact Detection Toolbox (ART; Gabrieli Laboratory, McGovern Institute for Brain Research, Cambridge MA) to detect spikes in global mean response and motion outliers in the functional data. Motion parameters will be included as regressors in the design matrix at individual-level analysis. To identify brain regions activated in response to exposure to thin women and high-calorie foods, we will contrast fMRI BOLD response during the presentation of thin women/high-calorie food images versus images of average-weight women/glasses of water.To identify brain regions activated in response to food receipt we will contrast BOLD response during receipt of milkshake verses tasteless solution. To identify brain regions activated in response to anticipated milkshake receipt we will contrast BOLD response during the cue for impending milkshake receipt versus the cue for impending tasteless solution receipt. To identify brain activation in response to inhibitory control to high-calorie foods, we will contrast successfully inhibited response to no-go dessert trials versus no-go vegetable trials. For the delay discounting task, the rate at which the subjective value of a reward decays with delay (TD rate) will be assessed through Mazur's (1987) equation: Vd = V/ (1+kD), where Vd represents the discounted value at D delay, V is the undiscounted amounted, and k is the estimated discounted parameter. High values of k indicate a preference for immediate rewards. Vd will be derived by calculating individuals' indifference point -the value of the immediate snack reward that is considered as attractive as the 40 units delayed snack reward. Indifference points will be calculated for each delay and fit to the hyperbolic model of delay discounting rate (k) and then log transformed (lnk). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05133037
Study type Observational
Source Stanford University
Contact Kristen Gee, B.S.
Phone 650-285-2049
Email ktgee@stanford.edu
Status Recruiting
Phase
Start date November 23, 2021
Completion date September 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05656859 - Prevalence of Eating Disorders Among Patients in the Department of Health Promotion
Completed NCT04085861 - Mental Health in Dancers; an Intervention Study N/A
Recruiting NCT05651295 - A Precision Medicine Approach to Target Engagement for Emotion Regulation N/A
Enrolling by invitation NCT04174703 - Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing N/A
Terminated NCT04278755 - Binge Eating & Birth Control Phase 2
Withdrawn NCT03050632 - Effects of Cognitive and Emotional Functioning on Treatment Outcomes N/A
Completed NCT02567890 - Swedish Body Project for Prevention of Eating Disorders N/A
Completed NCT02484794 - Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application N/A
Completed NCT02252822 - Improving Treatment Engagement for Adolescents With Bulimia Nervosa N/A
Completed NCT02021344 - Mental Health First Aid for College Students N/A
Completed NCT00601354 - Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder N/A
Completed NCT00418977 - Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents N/A
Completed NCT00304187 - Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa Phase 2
Completed NCT00733525 - Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa N/A
Active, not recruiting NCT04779216 - Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa Phase 3
Completed NCT04433663 - Eating Disorders, Self Regulation and Mentalization N/A
Recruiting NCT05509257 - Naltrexone Neuroimaging in Teens With Eating Disorders Early Phase 1
Completed NCT04509531 - Building Resilience in Cyberbullying Victims N/A
Recruiting NCT05730348 - Mealtime Anxiety in Eating Disorders
Enrolling by invitation NCT05814653 - A Study to Evaluate Primary Care Treatment for Adolescent Eating Disorders N/A